Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

Dizzier47 Jul. 30 at 3:19 PM

$PRLD full porting this yolo, if their drug sucks then ill be out sucking for drugs

1 · Reply

Dizzier47 Jul. 29 at 6:05 PM

$PRLD close to delist notice but also close to data release, but the delist will take in effect next year so there might not be a need for any reverse splits if they believe in their drug

0 · Reply

LabPsycho Jul. 29 at 5:45 PM

$PRLD @Jaybird827 I think a pivot event happened yesterday, ergo, yes, up or down (significantly) which would be a change from the same ole same ole ~85 cents +/- a few pennies.

0 · Reply

Dizzier47 Jul. 29 at 5:41 PM

$PRLD its going up down or sideways

0 · Reply

LabPsycho Jul. 29 at 2:20 PM

$PRLD Based on my chart analysis, a move is coming (up or down). Yesterday's dump and recovery on low volume and todays spike and retrace on low volume = trigger event has happened IMO. Could it be they received a delisting notice? Looks to me like getting close to 180 days below $1. On the other hand, encouraging clinical data leak? In either case, I do not see this continuing to trade in the ~85-90 cent range much longer. Rebuttals, alternate hypotheses?

1 · Reply

LabPsycho Jul. 28 at 6:46 PM

$PRLD Hmm...a 200k then another 100k dump this morning knocking it down to 79 cents is either an omen or a cleanout?

1 · Reply

Dizzier47 Jul. 22 at 7:05 PM

$PRLD give me the data and send me to valhalla

1 · Reply

JBurckhardt Jul. 10 at 2:32 PM

$PRLD assets worth ~500 million

1 · Reply

Gellener Jul. 1 at 12:44 PM

$PRLD catching @ 0.60

1 · Reply

BioTechHealthX Jun. 19 at 6:27 AM

$PRLD Prelude Therapeutics is targeting the toughest cancers with first-in-class degraders. This company could deliver massive returns. https://biotechhealthx.com/biotech-news/is-prelude-prld-the-next-biotech-titan-investors-are-watching-this-stock-closely/

0 · Reply

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 6, 2025, 4:05 PM EDT - 3 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:30 AM EDT - 3 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 25, 2025, 4:05 PM EDT - 3 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Mar 10, 2025, 7:30 AM EDT - 5 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 5, 2025, 7:30 AM EST - 5 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 8 months ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Nov 27, 2024, 7:30 AM EST - 8 months ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Oct 24, 2024, 7:30 AM EDT - 10 months ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 10 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 10:00 AM EDT - 11 months ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 11 months ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 1 year ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 1 year ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Feb 9, 2023, 9:05 AM EST - 2 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Nov 14, 2022, 8:00 AM EST - 2 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 11, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 9, 2022, 8:05 AM EST - 3 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Feb 11, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Jan 4, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Nov 23, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Nov 12, 2021, 8:00 AM EST - 4 years ago

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Nov 8, 2021, 9:00 AM EST - 4 years ago

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Oct 7, 2021, 12:55 PM EDT - 4 years ago

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Oct 7, 2021, 9:00 AM EDT - 4 years ago

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Aug 12, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Jul 27, 2021, 12:32 PM EDT - 4 years ago

Why BofA Is Turning Bullish On Prelude Therapeutics

May 11, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

Mar 3, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

Dizzier47 Jul. 30 at 3:19 PM

$PRLD full porting this yolo, if their drug sucks then ill be out sucking for drugs

1 · Reply

Dizzier47 Jul. 29 at 6:05 PM

$PRLD close to delist notice but also close to data release, but the delist will take in effect next year so there might not be a need for any reverse splits if they believe in their drug

0 · Reply

LabPsycho Jul. 29 at 5:45 PM

$PRLD @Jaybird827 I think a pivot event happened yesterday, ergo, yes, up or down (significantly) which would be a change from the same ole same ole ~85 cents +/- a few pennies.

0 · Reply

Dizzier47 Jul. 29 at 5:41 PM

$PRLD its going up down or sideways

0 · Reply

LabPsycho Jul. 29 at 2:20 PM

1 · Reply

LabPsycho Jul. 28 at 6:46 PM

$PRLD Hmm...a 200k then another 100k dump this morning knocking it down to 79 cents is either an omen or a cleanout?

1 · Reply

Dizzier47 Jul. 22 at 7:05 PM

$PRLD give me the data and send me to valhalla

1 · Reply

JBurckhardt Jul. 10 at 2:32 PM

$PRLD assets worth ~500 million

1 · Reply

Gellener Jul. 1 at 12:44 PM

$PRLD catching @ 0.60

1 · Reply

BioTechHealthX Jun. 19 at 6:27 AM

0 · Reply

Jaybird827 Jun. 9 at 10:55 PM

$PRLD anyone have an idea of why this is running? Thanks

0 · Reply

Dizzier47 Jun. 9 at 10:02 PM

$PRLD money coming into biotech stocks again, if this company has good data on their drugs it's rocketing

0 · Reply

Nakuneballe Jun. 9 at 6:10 PM

$PRLD patience is key 🙏

0 · Reply

elitechrisvp Jun. 9 at 5:47 PM

$TPST good day! $IBRX $PRLD

0 · Reply

elitechrisvp Jun. 9 at 5:38 PM

$PRLD 😁👍

0 · Reply

BobBijawklah Jun. 4 at 5:26 PM

$BMEA next runner is $PRLD. cash value 2.20 cent share trading at 1.00 dollar . just broke the dollar mark

1 · Reply

Windowphil May. 27 at 1:12 PM

$PRLD lots of insider buying, CEO did well at a previous company

0 · Reply

garygb May. 26 at 7:43 PM

$PRLD I like the Analysts bullishness.

0 · Reply

BigSqueezeComing May. 24 at 11:13 PM

$PRLD new to this stock. why is everyone so bullish? give me reason to invest

0 · Reply

PenkeTrading May. 14 at 1:19 PM

I found you a MACD Bearish Reversal Divergence on the daily chart of Prelude Therapeutics Inc. $PRLD #Prelude #BearishReversalDivergence #NASDAQ

0 · Reply

JBurckhardt May. 13 at 9:41 PM

$ABCL partner $PRLD (underrated and undervalued) ended the day up 13%

0 · Reply

Windowphil May. 13 at 3:40 PM

$NKGN don’t sleep on $PRLD, analysts have it going to $5

1 · Reply

Market Cap	46.77M
Revenue (ttm)	7.00M
Net Income (ttm)	-127.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,816.71%
Debt to Equity Ratio	0.00

Volume	74,500
Avg Vol	173,000
Day's Range	N/A - N/A
Shares Out	56.46M
Stochastic %K	23%
Beta	1.22
Analysts	Sell
Price Target	$3.75